Business Wire

FPT-SOFTWARE

15.3.2024 10:12:32 CET | Business Wire | Press release

Share
FPT Expands Global Presence with New Subsidiary in Dalian, China

Global IT company FPT announced the inauguration of its new extension in China, FPT Dalian. Leveraging its highly skilled workforce with diverse language proficiencies, the new subsidiary is poised to enhance support to companies in Japan and China, with a future direction of broadening its global customer base.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240315542507/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The inauguration was attended by government representatives, Japanese and Chinese partner companies, FPT executives, and other distinguished guests. (Photo: Business Wire)

The strategic move allows FPT to gain access to a high-quality talent pool of over 200,000 Japanese-proficient IT engineers and a network of top-notch universities with ICT training, serving its initial focus on supporting existing Japanese customers. Combined with FPT's well-established position in Japan and global resources, it can extend support and provide end-to-end digital solutions to other Chinese businesses and thousands of Japanese companies operating here.

Located in the high-technology zone for leading enterprises, such as Canon, Amazon, and KPMG, this new office allows the firm to stay closer to its existing customers and further expand its Chinese presence.

According to Mdm. Chu Thi Thanh Ha, Chairwoman of FPT Software (a subsidiary of FPT), FPT Dalian, not only enables the company to further accompany businesses in the region but also serves as a commitment to the governments of China, Japan, and Vietnam. “As a leading IT firm in Vietnam, we aim to serve as a bridge for economic corporations between China, Japan, and Vietnam. We believe FPT Dalian can actively help strengthen relationships and promote cross-border collaborations among companies here.” she pledged.

According to FPT Dalian CEO Pham Thanh Tuan, the firm plans to expand its local workforce to 2,000-3,000 employees within the next three to five years. To realize this goal, it is committed to close collaborations with universities and other educational institutions in Dalian to provide ICT training and career opportunities.

The establishment of FPT Dalian also received support from the local authorities, marked by Dalian government representatives' recent visit to FPT. Here, the government delegation expressed strong support for FPT's Dalian branch and its vision for the city's socioeconomic development.

After nearly two decades of operating in Japan, FPT Japan has become one of Japan's largest foreign-invested tech firms in terms of human resources. With a workforce of 3,000 onsite employees, nearly 15,000 employees working from overseas, 16 local offices and innovation hubs, FPT Japan has provided services and solutions to over 450 clients worldwide. The company is also recognized for excellent employee benefits and workplace happiness, earning accolades such as Best Workplaces in Asia, Best Places to Work in Japan, and Best Places to Work for Women in Japan.

Before FPT Dalian, FPT has developed a solid presence in China, with offices in Shanghai and Nanning, launched in 2017 and 2023, respectively, and has formed strategic partnerships with key Chinese players in the automotive and semiconductor sectors.

The new office is located at No.1, Hui Xian Yuan, Dalian Hi-tech Industrial Zone, Dalian, 116025, China.

About FPT Corporation

FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of US$2.17 billion and 70,000+ employees. For more information, please visit https://fpt.com.vn/en.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240315542507/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release

Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and

Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye